Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial.

Charlotte L B M Korst, Wouter Plattel, Elizabeth A de Kort, Febe Smits, Alexandra J Croockewit, Mark-David Levin, Matthijs Westerman, Okke de Weerdt, Inger S Nijhof, Jurgen Wegman, Nina Smit, Christie P M Verkleij, Tuna Mutis, Kazem Nasserinejad, Ramses Kerstiens